Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. In 2015, an estimated 60,600 new cases were diagnosed in Mainland China, accounting for 40% of all cases worldwide [1]. The Tumor-Node-Metastasis (TNM) staging system of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) is the most important tool for guiding treatment strategies in clinical practice. Radiotherapy alone is the recommended approach for stage I NPC, and concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy is the first choice for locoregionally advanced NPC (LANPC; stage III-IV, without distant metastasis) [2,3].
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2s91AC7
via IFTTT
Κυριακή 28 Μαΐου 2017
Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.